top of page
Image (4).jpeg

Meet Hopewell

Delivering Hope and Wellness

Hopewell is a privately held biotechnology company based in Woburn, Massachusetts.  It was founded by Dr. Qiaobing Xu, Professor of Biomedical Engineering at Tufts University and a world-renowned leader in the application of material science engineering to biomedicine, with a focus on advancing the field of genomic medicine with leading-edge lipid nanoparticle (LNP) delivery technology. The company established operations with a seed financing round in January 2022.


Leveraging an extensive intellectual property portfolio licensed from Tufts and augmented at Hopewell, the company specializes in synthesizing and developing targeted, efficient, and safe LNPs supporting diverse cargoes to address unmet medical needs through its differentiated ATLAS platform. 


Hopewell’s LNP platform serves as an engine for both internal pipeline programs and external collaborations. With a fully operational lab and an experienced team, Hopewell has established broad R&D capabilities spanning lipid synthesis, mRNA cargo development, and LNP development.  

Executive Team

Deep Expertise in Novel LNP Delivery Systems and Building Successful Biopharma Companies


Chief Executive Officer

Image (3).jpeg

Chief Scientific Officer

qiaobing xu_edited.jpg

Founder, Chief Technology Officer; Professor, Tufts University


Chief Operating Officer

Headshot GAS_edited.jpg

Strategy Consultant

Board of Directors

Louis Brenner

Chief Executive Officer

Qiaobing Xu

Scientific Founder and
Chief Technology Officer

Howie Rosen

Executive Chairman

Tom Hennessey III

Mass Ave Capital

Ted Jing

5Y Capital

Jake Xia

Harvard Management Company

Scientific Advisors

Institute Professor, MIT

Professor, Harvard Medical School

bottom of page